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Abstract
Transcatheter aortic valve implantation (TAVI) is a well-established treatment for symptomatic severe aortic 
stenosis in intermediate and high-risk patients. However, as TAVI indications increase, concerns regarding adverse 
events and complications rise in the same proportion. Stroke is one of the most feared TAVI complications and a 
hard endpoint present in all TAVI studies. TAVI-related stroke incidence becomes even more relevant with TAVI 
indications spreading to younger, low/intermediate-risk patients. Several devices have been developed to prevent 
this catastrophic event, some of them being broadly used. Nevertheless, the evidence for routine use of cerebral 
embolic protection devices is still controversial.
Keywords: Transcatheter aortic valve replacement, transcatheter aortic valve implantation, cerebral protection 
device, cerebral protection system, Sentinel Cerebral Protection System, stroke prevention
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is a well-established and widespread option to treat severe 
aortic stenosis in intermediate and high-risk patients. However, its increased use brings some intrinsic 
concerns, especially in low-risk and younger patients, a population in which even a low rate of adverse 
events can be catastrophic
[1-7]
. In this setting, to reduce or, ideally, to eliminate neurological complications 
is especially relevant. 
To mitigate neurological events risk, cerebral embolic protection devices (CEPD) were developed aiming to 
capture embolized debris and/or to prevent them from reaching the cerebral circulation. Even with some 
evidence supporting CEPD benefits and safety, the lack of a single randomized clinical trial demonstrating 
reduction in hard outcomes, such as stroke and mortality, has limited the widespread acceptance of CEPD 
and its routine use. 
This article offers an updated state-of-the-art review on CEPD use and which patient profile is most likely 
to benefit from this therapy.
Issue relevance
The incidence of clinically relevant neurological events after TAVI varies from 1 to 10%, but it can be as 
high as 94% if silent events detected by brain imaging are also considered
[8]
. The majority of post-TAVI 
strokes have an embolic origin and occur in the early post-TAVI period (64% and 85% at 2 and 7 days, 
respectively). These are referred to as procedure-related neurological events. 
Calcium debris embolization can happen during catheter and wire manipulation, valve implantation, pre-
dilatation, and/or post-dilatation
[2,5]
. Compared to native valves, valve-in-valve and bicuspid aortic valve 
are associated with higher stroke rates due to the need for increased valve manipulation or the presence 
of highly calcified anatomies. Debris embolization can also be secondary to small thrombus formation or 
embolization from atherosclerotic plaques in the ascending aorta and aortic arch.
Regarding the clinical relevance, patients who suffer a stroke are at high risk for mortality and severe 
morbidity including physical disability
[9,10]
. In a meta-analysis conducted by Eggebrecht et al.
[11]
, patients 
with cerebrovascular events presented a 3.5-fold higher 30-day mortality than those without events (25.5% 
vs. 6.9%, respectively). In another study, short- and long-term mortality risks were incremental according 
to cerebrovascular events severity, with a significantly higher mortality rates in the presence of major 
stroke [30-day mortality: odds ratio (OR) = 7.43; 95% confidence interval (CI): 2.45-22.53; P = 0.001, late 
mortality: hazard ratio (HR) = 1.75; 95%CI: 1.01-3.04; P = 0.043]
[12]
. Similarly, a meta-analysis of 29,034 
patients showed a 30-day mortality following stroke of 12.27%, with stroke-related mortality of 28.22%, 
compared with 6.4% mortality in patients without a stroke (OR = 6.45; 95%CI: 3.9-10.66; P < 0.0001)
[13]
. 
Furthermore, it is valid to emphasize that 30-day permanent disability is found in around 50% of patients 
who have suffered a stroke
[14]
 and that even silent cerebral emboli are associated with worse outcomes, three 
times higher risk of clinical stroke, two times higher risk of dementia and declined cognitive function.
Notwithstanding, cerebrovascular events present a high impact on patient’s quality of life, a consequence 
even more feared than death. Interesting research showed that, in terms of postoperative perspectives, 
the majority of patients undergoing TAVI had as their primary objective the maintenance of their 
independence and being able to practice daily hobbies, but only 7% had staying alive after the procedure 
as their main goal
[15]
. These results highlight the importance of patients’ quality of life as endpoint, which 
should be considered during the TAVI decision-making process. 
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CEREBRAL PROTECTION SYSTEM
Recent data suggested that CEPD use is associated with less overt strokes, lower total lesion volume, and a 




So far, several CEPD have been developed by many manufactures, including ProtEmbo, Sentinel, 
TriGUARD, Emblok, Emboline, Embrella, and Embol-X
[20-22]
. They vary not only in the mechanism for 
protection, for instance, capture versus deflection, but also in the access site and delivery sheath size [Table 1]. 
However, only the Sentinel is already approved by the Food and Drug Administration (FDA), being the 
most used and studied device. A summary of the current published and ongoing trials regarding cerebral 
protection during TAVI is presented in Table 2.
Sentinel CPS
R
 [Claret Medical (Boston Scientific, Corp, USA)]
The Sentinel CPS is the most studied cerebral protection device. It is made of 2 inter-connected filters 
deployed into the brachiocephalic trunk and left common carotid artery through a 6 French size sheath
[23]
. 
The most commonly used access is the right radial artery [Figures 1 and 2]
[18]
.
Three randomized clinical trials (RCT) evaluating the Sentinel’s role during TAVI were published in 2016, 
the MISTRAL-C, the CLEAN-TAVI, and the SENTINEL trial
[22,24,25]
. These trials demonstrated device’s 
safety and suggested that Sentinel was associated with fewer and smaller brain lesions on postoperative 
MRI than unprotected TAVIs.
The MISTRAL-C was the first study to enroll 65 TAVI patients submitted to a protected or unprotected 
TAVI procedure. New brain lesions on MRI studies were found in 78% of patients, with fewer new lesions 
number (73% vs. 87%; P = 0.31) and total lesion volume [95 mm
3
 (IQR 10-257) vs. 197 mm
3
 (95-525); P = 
0.171] in the protected group. Ten or more new brain lesions were found only in the control cohort (0% 
vs. 20%; P = 0.03), and neurocognitive deterioration was present in 4% of patients with received Sentinel 
during TAVI vs. 27% in those who did not (P = 0.017)
[24]
. Similarly, the CLEAN-TAVI study randomized 
100 patients in 1:1 fashion to TAVI with or without Sentinel insertion. Post-procedure MRI revealed new 
cerebral lesions in 98% of patients, with a significant smaller new lesion volume [242 mm
3
 (95%CI: 159-353) 
vs. 527 mm
3
 (95% CI 364-830); P = 0.001] and lower number of new lesions two days post-TAVI [4.0 (IQR: 
3.00-7.25) vs. 10.0 (IQR 6.75-17.00); P < 0.001] in the Sentinel group. These neuro-imaging differences, 
however, were not translated into a significant reduction in clinical stroke incidence (10% in each group)
[22]
. 
The randomized SENTINEL trial, by its time, included 363 patients with a 2:1 randomization for CEPD vs. 
no CEPD. Although statistical significance was not achieved, the study demonstrated a strong trend toward 
stroke reduction within 72 h post-TAVI in the CEPD group compared to the unprotected group (3.0% vs. 
8.2%; P = 0.053)
[25]
.
Table 1. Main cerebral protection devices
Coverage Access site Delivery sheath Pore size Mechanism
Sentinel BCT, LCCA Radial 6F 140 μm Capture
TriGUARD Full arch Femoral 8F 115 × 145 μm Deflection
Embrella BCT, LCCA Radial 6F 100 μm Deflection
ProtEmbo Full arch Radial 6F 60 μm Deflection
Emblok Full arch Femoral 11F 125 μm Capture
Embol-X Full body Transaortic 17F 120 μm Capture
Emboliner Full body Femoral 9F 150 μm Capture
































































Study design Endpoints Population Main results (device vs.  no device)
Published trials
MISTRAL-C 2016 Sentinel (CE 




Primary endpoint: new cerebral lesions by DW-MRI 5 
to 7 days after TAVI
From January 2013 to 
July 2015, 65 patients 
randomized 1:1 to 
transfemoral TAVI with 
or without Sentinel 
Device success: 93%
New brain lesions: 78%
Absence of new lesions: 13% vs. 27%; P = 0.31
Total lesion volume: 95 mm
3




≥ 10 new brain lesions: 0 vs. 20%; P = 0.03
Neurocognitive deterioration: 4% vs. 27%; P = 0.017
CLEAN-TAVI 2016 Sentinel Randomized 
clinical trial
Primary endpoint: numerical difference in new positive 
postprocedure DW-MRI brain lesions at 2 days after 
TAVI in potentially protected territories. 
Secondary outcome: difference in volume of new 
lesions after TAVI in potentially protected territories
From April 2013 to June 
2014, 100 patients 
randomized 1:1 to TAVI 
with or without Sentinel
Device success: 92%
New cerebral lesions: 98%
Number of new lesions: 4 (3-7.25) vs. 10 (6.75-17); P < 
0.001
New lesion volume: 242 mm
3
 (159-353) vs. 527 mm
3
 
(364-830); P = 0.001
Stroke incidence: 10% vs. 10% 
SENTINEL 
trial
2017 Sentinel Randomized 
clinical trial
Primary safety endpoint: MACCE at 30 days
Primary efficacy endpoint: reduction in new lesion 




randomized 2:1 to TAVI 
with or without Sentinel 
Device success: 94.4%
Debris found within filters: 99%
MACCE: 7.3% vs. 9.9%; P = 0.41
New lesion volume: 102.8 mm
3
 vs. 178 mm
3
; P = 0.33
30 days stroke: 5.6% vs. 9.1%; P = 0.25







Primary safety endpoint: in-hospital device- or 
procedure-related cardiovascular mortality, major 
stroke disability, life-threatening bleeding, distal 
embolisation, major vascular complications, or need 
for acute cardiac surgery
37 consecutive patients 
undergoing TAVI with 
the TriGuard
Successful cerebral coverage: 80%
Primary outcome: 8.1%
New cerebral ischaemic lesions on post-procedure 
DW-MRI: 82%
Per-patient total lesion volume: 34% lower than 





DEFLECT III 2015 TriGuard Randomized 
clinical trial
Primary endpoint: in-hospital procedural safety (death, 
stroke, life-threatening or disabling bleeding, stage 2/3 
acute kidney injury, or major vascular complications)
Secondary device performance endpoint: technical 
success (successful device deployment, positioning 
with complete three-vessel coverage)
13 centers in Europe and 
Israel
From February 2014 to 
March 2015, 85 patients 
randomized to TAVI 
with (n = 46) or without 
TriGuard (n = 39)
Primary endpoint: 21.7% vs. 30.8%; P = 0.34
Technical success: 88.9%
Per Treatment population (subjects with complete 
three-vessel cerebral coverage): new ischaemic brain 
lesions 26.9 vs. 11.5%); new neurologic deficits 3.1 vs. 
15.4% 
REFLECT II 2020 TriGuard 3 Randomized 
clinical trial
Primary safety endpoint (composite of all-cause 
mortality, stroke, life-threatening or disabling bleeding, 
stage 2/3 acute kidney injury, coronary artery 
obstruction requiring intervention, major vascular 
complication, and valve-related dysfunction requiring 
intervention at 30 days
Primary efficacy endpoint (composite of all-cause 
mortality or stroke at 30 days, National Institute of 
Health Stroke Scale worsening, absence of DWI-MRI 




randomized 2:1 to TAVI 
with or without TriGuard 
3 
Device successful deployment: 100%
Technical success: 71%
Primary safety endpoint: 15.9% device vs. 34.4% 
performance goal; P non-inferiority = 0.0001
Primary efficacy endpoint: 45.7% vs. 54.3%; P = 0.857 
Median total lesion volume: 215.39 mm
3
 vs. 188.09 
mm
3



































































Periprocedural cerebral lesions assessed by DW-MRI 52 patients who 
underwent transfemoral 
TAVI with (n = 41) 
or without (n = 11) 
Embrella 
Device successfully deployed: 100%
7 days DW-MRI new ischemic lesions: 100% vs. 
100% 
Median number of defects per patient: 8 (3-13) vs. 4 
(2-8); P = 0.41
Lesion volume per lesion: 30 mm
3
 (20- 50) vs. 50 
mm
3
 (30-70); P = 0.003
EMBOL-X 
trial




Periprocedural cerebral lesions assessed by DW-MRI 
at baseline and within 7 days post-TAVI
From July 2012 to April 
2014, 30 patients 
randomized 1:1 to TAVI 
with (n = 14) or without 
EMBOL-X (n = 16)
New foci of restricted diffusion: 57% vs. 67%; P = 0.7 
Lesion size: 88 ± 60 mm
3
 vs. 168 ± 217 mm
3
; P = 0.27
Lesion volumes in the supply region of the middle 
cerebral artery: 33 ± 29 mm
3
 vs. 76 ± 67 mm
3










Primary endpoint: technical success and immediate 
cerebral embolic burden after TAVI (number and 
volume of new brain lesions detected by DW-MRI at 
days 2 to 5 post-TAVI compared with baseline)
20 patients submitted 
to TAVI with Emblok
Device successfully positioned: 100%
Significant debris capture: 90%
30-day MACCE: 0% 
New ischemic defect post-procedural DW-MRI: 95%
Median number of new lesions per patient: 10 (4.75-
15.2) 
Total new lesion volume: 199.9 mm
3
 (83.9-447.5)
Mean lesion volume per lesion: 42.5 mm
3
 (21.5-75.6)










Primary safety endpoint: 30-day MACCE incidence
Technical performance: technical success (ability to 
successfully access the aortic arch, position the device 
and retrieve and remove it) 
3 centers in New 
Zealand 
24 patients
submitted to TAVI with 
Emboliner
Primary safety endpoint: 0%










rate of stroke through 72 hours post-TAVR or discharge 
(whichever comes first) 
Estimated enrollment: 
3000 patients 
randomized to TAVR 







Primary endpoint: total new lesion volume in protected 
brain regions detected by MRI 
Secondary endpoint: number of new cerebral lesions 
detected by MRI; occurrence of clinical stroke and/or 
neurocognitive dysfunction; postoperative outcome 
according to VARC 2 criteria 
Estimated enrollment: 
328 patients submitted 













Primary endpoint: procedural success (successful 
access, delivery to, deployment within, and retrieval of 
the ProtEmbo System from the aortic arch, adequate 
coverage of side branch vessels and maintenance of 
position for duration of the TAVR procedure)
In-hospital procedural safety up to 7 days (MACCEs, 
including device-related safety outcomes)
Stroke severity at 3 and 30 days 
Occurrence of Serious Adverse Events at 3 and 30 
days 
Original estimated 
enrollment: 10 patients 
submitted to TAVI with 
ProtEmb
MACCE: major adverse cardiac and cerebrovascular events; DWI-MRI: diffusion-weighted magnetic resonance imagingt
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Figure 1. Sentinel cerebral protection system. Image provided courtesy of Boston Scientific. © 2020 Boston Scientific Corporation or its 
affiliates. All rights reserved
Figure 2. Sentinel implantation
Regardless of the fact that none of these trials have, individually, demonstrated superiority in terms of hard 
outcomes, such as stroke and mortality, recent meta-analyzes showed that CEPD use was associated with 
lower rates of stroke and 30-day mortality
[18,23]
. A propensity-matched patient cohort including 533 patients 
also showed lower rates of procedural all-stroke (1.88% vs. 5.44%, OR = 0.35, 95%CI: 0.17-0.72, relative risk 
reduction 65%; P = 0.0028), and the combined endpoint of all-cause mortality and all-stroke (2.06% vs. 
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6.00%, OR = 0.34, 95%CI: 0.17-0.68, relative risk reduction 66%; P = 0.0013) in the protected TAVI group. 
The rate of disabling stroke was also substantially lower in the Sentinel group (0.38% vs. 2.44%; P = 0.0045)
[26]
. 
Furthermore, in the last months, evidence from two large US databases has suggested that Sentinel use 
during TAVI was associated with statistically significant reduction in stroke risk. In the Society of Thoracic 
Surgeons/American College of Cardiology (STS/ACC) TVT Registry, the rate of in-hospital stroke was not 
significantly lower when the Sentinel device was used according to an instrumental-variable analysis (1.39% 
vs. 1.54%; RR = 0.90; 95%CI: 0.68-1.13). A secondary propensity-weighted analysis of the data, however, 
indicated that cerebral protection was associated with a reduction in the rates of in-hospital stroke (1.30% 
vs. 1.58%; RR = 0.82; 95%CI: 0.69-0.97), in-hospital death or stroke (2.1% vs. 2.5%; RR = 0.84; 95%CI: 0.73-
0.98), 30-day stroke (1.9% vs. 2.2%; RR = 0.85; 95%CI: 0.73-0.99), and 30-day death (1.7% vs. 2.2%; RR = 0.78; 
95%CI: 0.64-0.95)
[27]
. Corroborating these findings, a propensity-weighted analysis of the National Inpatient 
Sample showed that Sentinel use was associated with a lower risk of in-hospital ischemic stroke (1.0% vs. 
3.8%; OR = 0.24; 95%CI: 0.09-0.62) and in-hospital death (0% vs. 1%; P = 0.036)
[28]
.
Despite the aforementioned, it is essential to remember that the Sentinel does not protect the left vertebral 
artery since it is a branch of the left subclavian artery. There are still concerns about leaving the left 
vertebral artery unprotected, thus some companies are developing devices to eliminate this blind spot. 
TriGUARD
TM
 (Keystone Heart, Herzliya, Israel)
The TriGUARD is the only CE mark approved system designed to cover and protect all three major cerebral 
aortic arch vessels [Figure 3]. Currently, the device is only in investigational use in the US, planning to 
apply for FDA approval.
The TriGUARD is inserted through a transfemoral 8F sheath, via the femoral artery access already in use 
during TAVI, usually at the pigtail insertion side, thus eliminating the need for a third arterial puncture. 
The device is made of nitinol and consists of a self-positioning, self-stabilizing polymetric mesh with pore 
sizes 115 × 145 micrometers (μm) opened in the aortic arch, covering the three aortic arch vessels[29].
There are clinical trials already published showing the efficacy and safety of the device. The DEFLECT I 
and DEFLECT III trial demonstrated that the technical success, which included complete 3-vessel cerebral 
coverage, was achieved in 80%-90% of the patients. The DEFLECT III demonstrated that this device use is 
Figure 3. TriGUARD device
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associated with greater freedom from new ischemic brain lesions, fewer new neurologic deficits, and better 
performance on a delayed memory task at hospital discharge
[30,31]
. From DEFLECT I to DEFLECT III study, 
the device has changed from a 250 μm to 130 μm pore size. The REFLECT trial is another randomized 
clinical trial with larger population, designed to study the TriGUARD 3 device. The TriGUARD 3 is the 
new generation device, designed to bring some improvements such as a simplified frame design, which 
eliminates the need for a dedicated stabiliser. It is fully visible via fluoroscopy, contains a reduced filter 
mesh pore size for deflection of smaller particles (145 µm × 115 µm vs. 250 µm × 250 µm), and has a refined 
delivery system that reduced the delivery profile (8F instead of 9F)
[32]
. Recently, Jeffrey W. Moses presented 
the results from the Reflect II trial during a late-breaking trial session at TCT Connect 2020. The results 




Embrella Embolic Deflector System (Edwards Lifesciences, Irvine, CA, USA)
The Embrella Embolic Deflector (EED) system consists of an oval-shaped nitinol frame (length 59 mm, 
width 5-25 mm), covered with a porous polyurethane membrane (100 μm pore size). Its porous membrane 
allows blood flow to the brain while simultaneously deflecting embolic material [Figure 4]. The device is 
composed of 2 petals and a delivery cable in a 6F sheath system inserted via the right radial or brachial 
arteries. The two opposing petals are positioned along the aorta greater curvature, protecting the 
brachiocephalic and common carotid arteries from embolism
[34,35]
.
The EED System has been assessed in a limited clinical study in Europe and received CE Mark approval in 
May 2010. Two main RCT have studied the EED system. In these studies, Rodés-Cabau et al.
[34]
 (PROTAVI-C 
Pilot) and Samim et al.
[35]
 demonstrated the feasibility and safety of using the EED. However, the device 
failed to prevent cerebral microemboli or new transient ischemic lesions, as evaluated by Diffusion 
Weighted Imaging Magnetic Resonance Imaging (DW-MRI). In fact, the studies showed a higher number 
of brain lesions in the EED group compared to the control group, even though the device was associated 
with lower lesion volume
[34,35]






 (Prtembis, GmbH, Germany)
The ProtEmbo is an intra-aortic embolic protection filter device comprising a filter connected to a delivery 
unit enabling delivery of the unexpanded device with a 6F sheath via the left radial artery [Figure 5]. The 
device is delivered in the aortic arch, protecting its three major vessels (i.e., brachiocephalic trunk, left 
Figure 4. Embrella device. Reproduced from Samim et al.
[35]
. A: the Embrella Embolic Deflector System; B: device positioned in the aortic 
arch; C: TAVI deployment
A B C
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common carotid artery, and left subclavian artery). The filter consists of a porous polymeric material with 
60 μm pores. The PROTEMBO SF Trial is the first randomized clinical trial to test the ProtEmbo device 
clinically. It has already completed the recruitment phase, but the results have not been published yet.
Emblok (Innovative Cardiovascular Solutions, Grand Rapids, MI, USA)
The Emblok embolic protection system is an 11F sheath device containing a 4F pigtail, delivered via 
femoral artery access in the aortic arch [Figure 6]. The device covers all three aortic arch vessels, and the 
filter consists of 125 μm of polyurethane.
The first trial testing the device was published on JACC, in 2020, by Latib et al.
[37]
. This prospective, 
nonrandomized, multicenter study had no control group. Nevertheless, it demonstrated that the use of this 
device appears to be feasible and safe. It was successfully placed and retrieved in all twenty cases, and no 
neurological events were observed.
Figure 5. Illustration of ProtEmbo device
Figure 6. Illustration of Emblok device
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Embol-X (Edwards Lifesciences, Irvine, CA, USA) - Transaortic
The Embol-X device was first developed to be used during open-heart surgery at the aortic cannulation 
site [Figure 7]. A randomized clinical trial tested its effectiveness in TAVI by a transaortic approach. In 
this trial, the device was shown to be safe and effective in reducing the incidence and the volume of new 
cerebral lesions. The device is placed inside the aorta and is available in 5 sizes covering an aortic diameter 
of 22 to 40 mm. It is delivered by a 17F sheath
[38]
.
Emboliner Embolic Protection Catheter (Emboline)
TM
The Emboliner Cerebral Protection Catheter is the first device designed to prevent both cerebral and body 
embolism [Figure 8]. It is delivered through a transfemoral 9F sheath, the same sheath used for the 6F 
pigtail. Therefore, no additional access is required. Its pore size is 150 μm. The SafePass 2 trial is the first 
trial with the Emboliner device; it has completed enrollment but has not been published yet. However, the 
device seems to be safe and effective with little adverse events related to it, capturing up to five times more 
debris than Sentinel, according to informal data.
Cost-effectiveness analysis
There is no published cost-effectiveness analysis defining the real role of routine cerebral embolic 
protection device use during TAVI procedures. Therefore, the benefit of preventing a stroke should be 
balanced against the device costs, taking into consideration that strokes have an unpredictable, but often 
devastating impact, not only in terms of mortality but also in terms of sequelae (50% of patients develop 
permanent disability, more than 50% are unable to return to work, and more than 30% end up with serious 
financial problems). In this setting, Shiyovich et al.
[39]
 estimated that the cost added by a moderate disability 
Figure 7. Transaortic Emblo-X device. Reproduced from Wendt et al.
[38]
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due to a neurologic event is around $25,000, followed by a subsequent annual cost increase of up to 
$60.000. Hence, as the device cost (Sentinel CPS) is approximately $2,800, and the CEPD number needed 
to treat is around 20, CEPD cost-effectiveness is suggested.
DISCUSSION
To critically evaluate the CEPD trials presented above, some critical points should be taken into account. 
First, the studies showed important discrepancy between imaging and clinical outcomes since the 
observed reduction in new cerebral lesions number and volume did not reflect the expected benefit in hard 
outcomes. Trying to explain this discrepancy, it has been hypothesized that the lack of validated models to 
assess neurocognitive function in TAVI patients, the certain degree of pre-procedural cognitive dysfunction 
in some patients, and the high prevalence of inter and intra-observer variability for neurological tests, 
could blunt the real CEPD benefit
[15]
. Second, stroke incidence varies according to the study type, being 
significantly higher when the results are adjudicated based on formal neurologist clinical assessment (up 
to 10%) than when they are adjudicated by non-neurologists (2%-6%)
[24-26]
. Third, CEPD randomized trials 
have not been designed or powered to demonstrate an unequivocal impact on hard clinical endpoints. 
These observations make the search for preventive strategies even more relevant, especially in younger 
patients with longer life expectancy.
Regarding the best procedure strategy, we believe that it is still too early to affirm that CEPD should 
be universally used or that there is a specific patient population in which protected TAVI is more cost-
effective. During the TAVI decision-making process, several factors should be balanced, such as age, the 
amount of leaflet and/or left ventricular outflow tract calcification, and the presence of aortic plaques or 
atrial fibrillation
[26]
. Therefore, from our perspective and considering the available evidence discussed 
above, two strategies could be possible:
1. Tailored preventive strategy: If TAVI is performed in a center with limited CEPD availability, one 
possible strategy could be to limit its use to high-risk scenarios based on preoperative risk factors (e.g., 
age, previous atrial fibrillation, history of cerebrovascular events, renal failure, concomitant coronary 
artery disease), transoperative risk factors (e.g., increased catheter and guidewire manipulation, extremely 
severe aortic stenosis, complex valve-in-valve procedures, multiple valve repositioning maneuvers, need 
Figure 8. Illustration of Emboliner full body protection device
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for pre- and post-dilatation), and highly calcified anatomies (e.g., extensive atherosclerosis, complex aortic 
atheroma, bicuspid aortic valve, severe left ventricular outflow tract calcification).
2. Routine preventive strategy: If TAVI is performed in a center without CEPD use restrictions, one 
possible approach could be to offer it routinely as long as there is adequate anatomy, heart team indication, 
and patient concordance. This approach is based on the fact that captured debris are presented in almost all 
patients
[40]
, regardless of preoperative risk factors or type of device used.
CONCLUSION
This review article discusses the pros and cons of cerebral embolic protection use during TAVI procedures. 
Despite CEPD’s high cost, recent evidence, especially with the Sentinel system, has suggested that cerebral 
protection employment may lower stroke and even mortality rates. Ongoing and upcoming trials will help 
to fill some of the current evidence gaps related to CEPD use during TAVI.
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